Kinase
If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body.
Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.
Conditions that may lead to anemia include:
- Heavy periods
- Pregnancy
- Ulcers
- Colon polyps or colon cancer
- Inherited disorders
- A diet that does not have enough iron, folic acid or vitamin B12
- Blood disorders such as sickle cell anemia and thalassemia, or cancer
- Aplastic anemia, a condition that can be inherited or acquired
- G6PD deficiency, a metabolic disorder
Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache.
Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have.
NIH: National Heart, Lung, and Blood Institute
Kinase FDA Approved Drugs
ALUNBRIG [BrigatinibC29H39ClN7O2P]
RX
- 30mg (oral tablet)
90mg (oral tablet)
AriadApr 28, 2017
- Treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) who have progressed on or are intolerant to crizotinib.
ICLUSIG [Ponatinib HydrochlorideC29H27F3N6OClH]
RX
- eq 15mg base (oral tablet)
eq 30mg base (oral tablet)
eq 45mg base (oral tablet)
AriadDec 14, 2012
- A method for the treatment of leukemias.
- A method for treating acute lymphoblastic leukemia.
- A method for treating chronic myeloid leukemia.
- A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain.
- A method for treating philadelphia chromosome positive acute lymphoblastic leukemia.
- A method of treating chronic myelogenous leukemia.
JAKAFI [Ruxolitinib PhosphateC17H18N6H3O4P]
RX
- eq 10mg base (oral tablet)
eq 15mg base (oral tablet)
eq 20mg base (oral tablet)
eq 25mg base (oral tablet)
eq 5mg base (oral tablet)
Incyte CorpNov 16, 2011
- For the treatment of intermediate or high-risk myelofibrosis.
- For the treatment of polycythemia vera.
- Use of ruxolitinib (jakafi) for blocking signal transduction of janus associated kinases (jaks) jak1 and/or jak2.
- Use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2..
SPRYCEL [DasatinibC22H26ClN7O2SH2O]
RX
- 100mg (oral tablet)
140mg (oral tablet)
20mg (oral tablet)
50mg (oral tablet)
70mg (oral tablet)
80mg (oral tablet)
Bristol Myers SquibbMay 30, 2008
- A method for the treatment of a protein tyrosine kinase-associated disorder.
- A method for the treatment of cancer.
- A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia.
STIVARGA [RegorafenibC21H15ClF4N4O3]
RX
- 40mg (oral tablet)
Bayer HlthcareSep 27, 2012
- Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor.
SUTENT [Sunitinib MalateC22H27FN4O2C4H6O5]
RX
- eq 12.5mg base (oral capsule)
eq 25mg base (oral capsule)
eq 37.5mg base (oral capsule)
eq 50mg base (oral capsule)
Cppi CvJan 26, 2006
- Treatment of gastrointestinal stromal tumor with sunitinib.
- Treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroendocrine tumors, with sunitinib.
SYNRIBO [Omacetaxine MepesuccinateC29H39NO9]
RX
- 3.5mg/vial (subcutaneous powder)
Teva Pharms IntlOct 26, 2012
- Treatment of leukemia.
- Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).
XALKORI [CrizotinibC21H22Cl2FN5O]
RX
- 200mg (oral capsule)
250mg (oral capsule)
Pf Prism CvAug 26, 2011
- Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
ZYDELIG [IdelalisibC22H18FN7O]
RX
- 100mg (oral tablet)
150mg (oral tablet)
Gilead Sciences IncJul 23, 2014
- A method of disrupting leukocyte function, including as an inhibitor of pi3kdelta kinase.
- For the treatment of patients with cll, fl, or sll.
- For the treatment of patients with relapsed chronic lymphocytic leukemia.
- For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma.
- In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll).
- Inhibition on pi3k kinase.
ZYKADIA [CeritinibC28H36ClN5O3S]
RX
- 150mg (oral capsule)
Novartis Pharms CorpApr 29, 2014
- Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.